Russell Investments Group Ltd. Has $28.84 Million Holdings in Sanofi (SNY)
Russell Investments Group Ltd. lowered its position in Sanofi (NYSE:SNY) by 6.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 579,379 shares of the company’s stock after selling 40,556 shares during the period. Russell Investments Group Ltd.’s holdings in Sanofi were worth $28,844,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the business. Moors & Cabot Inc. raised its position in shares of Sanofi by 0.7% in the second quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock worth $311,000 after acquiring an additional 43 shares during the period. Strategic Global Advisors LLC raised its position in shares of Sanofi by 0.6% during the 2nd quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock worth $414,000 after purchasing an additional 54 shares during the last quarter. First City Capital Management Inc. raised its position in shares of Sanofi by 0.3% during the 2nd quarter. First City Capital Management Inc. now owns 38,389 shares of the company’s stock worth $1,839,000 after purchasing an additional 100 shares during the last quarter. Synovus Financial Corp raised its position in shares of Sanofi by 2.7% during the 2nd quarter. Synovus Financial Corp now owns 4,621 shares of the company’s stock worth $219,000 after purchasing an additional 122 shares during the last quarter. Finally, Toronto Dominion Bank raised its position in shares of Sanofi by 4.6% during the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after purchasing an additional 180 shares during the last quarter. Institutional investors and hedge funds own 9.30% of the company’s stock.
Shares of Sanofi (NYSE:SNY) opened at $45.37 on Thursday. Sanofi has a one year low of $38.45 and a one year high of $50.65. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The firm has a market cap of $112,938.35, a P/E ratio of 14.13, a PEG ratio of 2.47 and a beta of 0.88.
Several research analysts recently weighed in on SNY shares. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Cowen and Company restated a “market perform” rating and set a $52.00 price target (up previously from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. BidaskClub raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Argus reaffirmed a “buy” rating and set a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $53.50.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.